Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the potential of the epigenome, the company aims to create new therapeutic pathways that modify biological functions without changing the underlying DNA sequence. This approach seeks to provide effective treatments for complex and widespread diseases, positioning Tune Therapeutics at the forefront of advancements in epigenetic medicine.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Pulumi Corporation operates an infrastructure-as-a-code platform that facilitates the development, deployment, and management of cloud applications and infrastructure. Founded in 2017 and based in Seattle, Washington, Pulumi offers the Pulumi SDK, an open-source tool that enables developers and DevOps teams to utilize programming languages for defining and managing cloud services across various environments, including public, private, and hybrid clouds. The platform supports a range of application types, from serverless functions to containerized applications, and emphasizes collaboration among teams to streamline cloud engineering processes. By providing a consistent workflow for delivering and securing applications, Pulumi helps businesses effectively create modern applications and manage their cloud environments.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
AppSheet is a no-code platform that empowers business users to create powerful applications without the need for programming knowledge. Founded in 2014 and based in Seattle, WA, it allows users to connect with various data sources, including spreadsheets, relational databases, and cloud services. The platform facilitates the rapid development of customizable applications that can incorporate features such as offline access, workflow automation, and machine learning capabilities. These applications are designed to function across multiple platforms, including web, iOS, Android, and messaging services. AppSheet's focus on user-friendly app creation enables organizations to leverage their data effectively while adhering to IT governance and security standards.
Igneous Systems, Inc., founded in October 2013 and headquartered in Seattle, Washington, specializes in enterprise data center infrastructure and unstructured data management. The company offers a comprehensive as-a-Service solution that provides businesses with visibility, protection, and mobility for their unstructured data on a large scale. Igneous’s cloud-native, API-enabled platform integrates various unstructured data management functions, allowing organizations to maximize the value of their data while minimizing risks and optimizing IT resource utilization. Its services include consolidated backup, file system archiving, and efficient management of unstructured data, all aimed at enhancing workflow productivity for data-centric enterprises.
IOpipe is a DevOps platform specifically designed for serverless applications, managing billions of events monthly. It offers a comprehensive toolbox for developing, monitoring, and operating these applications, addressing the unique challenges that arise from the shift towards serverless computing. The platform features an open-source module that enables real-time telemetry, tracing, profiling, alerts, logs, and error tracking, allowing developers to gain insights into the performance and operations of their serverless functions, such as those running on Amazon Lambda. By adopting a customer-centric approach, IOpipe collaborates closely with users to resolve challenges effectively. The company emphasizes building a remote-first, diverse team committed to delivering a top-tier product for serverless development and operations.
Igneous Systems, Inc., founded in October 2013 and headquartered in Seattle, Washington, specializes in enterprise data center infrastructure and unstructured data management. The company offers a comprehensive as-a-Service solution that provides businesses with visibility, protection, and mobility for their unstructured data on a large scale. Igneous’s cloud-native, API-enabled platform integrates various unstructured data management functions, allowing organizations to maximize the value of their data while minimizing risks and optimizing IT resource utilization. Its services include consolidated backup, file system archiving, and efficient management of unstructured data, all aimed at enhancing workflow productivity for data-centric enterprises.
CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.
IOpipe is a DevOps platform specifically designed for serverless applications, managing billions of events monthly. It offers a comprehensive toolbox for developing, monitoring, and operating these applications, addressing the unique challenges that arise from the shift towards serverless computing. The platform features an open-source module that enables real-time telemetry, tracing, profiling, alerts, logs, and error tracking, allowing developers to gain insights into the performance and operations of their serverless functions, such as those running on Amazon Lambda. By adopting a customer-centric approach, IOpipe collaborates closely with users to resolve challenges effectively. The company emphasizes building a remote-first, diverse team committed to delivering a top-tier product for serverless development and operations.
SafeRide, Inc. is a digital health platform that specializes in non-emergency medical transportation (NEMT) services, enabling healthcare providers to efficiently book and manage rides for patients. Founded in 2015 and headquartered in San Francisco, the company offers a mobile application that allows users to schedule transportation quickly, receive appointment reminders, and track rides in real-time for enhanced safety and quality. SafeRide's services not only help prevent no-shows but also assist in identifying and managing at-risk patients before their conditions worsen. With a network that spans major cities including Los Angeles, Seattle, Portland, St. Louis, and New York, SafeRide aims to improve access to life-sustaining care for vulnerable populations while enhancing the overall patient experience and reducing healthcare costs.
Mighty AI delivers training data to companies that build computer vision models for autonomous vehicles. Its platform combines guaranteed accuracy with scale and expertise, thanks to its full stack of annotation software, consulting and managed services, proprietary machine learning, and global community of pre-qualified annotators.
Founded in 2014, Mighty AI is headquartered in Seattle, Washington.
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States.
The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress.
In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.
AppSheet is a no-code platform that empowers business users to create powerful applications without the need for programming knowledge. Founded in 2014 and based in Seattle, WA, it allows users to connect with various data sources, including spreadsheets, relational databases, and cloud services. The platform facilitates the rapid development of customizable applications that can incorporate features such as offline access, workflow automation, and machine learning capabilities. These applications are designed to function across multiple platforms, including web, iOS, Android, and messaging services. AppSheet's focus on user-friendly app creation enables organizations to leverage their data effectively while adhering to IT governance and security standards.
Mighty AI delivers training data to companies that build computer vision models for autonomous vehicles. Its platform combines guaranteed accuracy with scale and expertise, thanks to its full stack of annotation software, consulting and managed services, proprietary machine learning, and global community of pre-qualified annotators.
Founded in 2014, Mighty AI is headquartered in Seattle, Washington.
Turi is a machine learning platform that creates big data analytics products for its users. This open source project was initially intended for applying large scale machine learning to graph analysis. The functionality of its product has since been greatly expanded to include tables, text, as well as images and is now in broad use to make recommendations, detect fraud, conduct customer sentiment analysis, and generally build predictive apps at many notable e-tailers, service providers, and Fortune 5000 firms, including Zillow, ExxonMobil, StumbleUpon, Adobe, Pandora, and Bosch. Turi was launched as Dato in 2013 by Danny Bickson, Haijie Gu, Yucheng Low, Joseph Gonzalez, and Carlos Guestrin. It is based in Seattle, W.A.
Mighty AI delivers training data to companies that build computer vision models for autonomous vehicles. Its platform combines guaranteed accuracy with scale and expertise, thanks to its full stack of annotation software, consulting and managed services, proprietary machine learning, and global community of pre-qualified annotators.
Founded in 2014, Mighty AI is headquartered in Seattle, Washington.
Igneous Systems, Inc., founded in October 2013 and headquartered in Seattle, Washington, specializes in enterprise data center infrastructure and unstructured data management. The company offers a comprehensive as-a-Service solution that provides businesses with visibility, protection, and mobility for their unstructured data on a large scale. Igneous’s cloud-native, API-enabled platform integrates various unstructured data management functions, allowing organizations to maximize the value of their data while minimizing risks and optimizing IT resource utilization. Its services include consolidated backup, file system archiving, and efficient management of unstructured data, all aimed at enhancing workflow productivity for data-centric enterprises.
Turi is a machine learning platform that creates big data analytics products for its users. This open source project was initially intended for applying large scale machine learning to graph analysis. The functionality of its product has since been greatly expanded to include tables, text, as well as images and is now in broad use to make recommendations, detect fraud, conduct customer sentiment analysis, and generally build predictive apps at many notable e-tailers, service providers, and Fortune 5000 firms, including Zillow, ExxonMobil, StumbleUpon, Adobe, Pandora, and Bosch. Turi was launched as Dato in 2013 by Danny Bickson, Haijie Gu, Yucheng Low, Joseph Gonzalez, and Carlos Guestrin. It is based in Seattle, W.A.
Private Equity Round in 2013
Pure Energies Group is a Canadian company dedicated to assisting homeowners in adopting solar energy and home conservation products. With a commitment to being a trusted energy advisor, the company aims to benefit communities and future generations through sustainable energy solutions. Established under Ontario’s Green Energy Act, Pure Energies has expanded its operations internationally, particularly in the United States, following acquisitions of companies such as One Block off the Grid and Cooler Planet. With offices located in Toronto, Mississauga, and San Francisco, Pure Energies represents Canada in the growing global solar market, providing energy advisory services to facilitate the transition to renewable energy sources for homeowners.
Immunex Corporation is a biopharmaceutical company based in Seattle, Washington, that focuses on the development, manufacturing, and marketing of therapeutic products aimed at treating cancer, infectious diseases, and autoimmune disorders. Founded in 1981, the company is known for its notable products, including Enbrel, which treats rheumatoid arthritis, Novantrone for acute nonlymphocytic leukemia and prostate cancer-related pain, and Leukine for bone marrow transplant patients. Immunex utilizes immune system proteins that function as hormones to provide these therapies. The company had a strategic alliance with American Home Products and, in 2002, was acquired by Amgen, Inc.